Back to Search
Start Over
Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study.
- Source :
-
Pediatric blood & cancer [Pediatr Blood Cancer] 2018 Dec; Vol. 65 (12), pp. e27381. Date of Electronic Publication: 2018 Sep 19. - Publication Year :
- 2018
-
Abstract
- Little is known about the challenging treatment of pediatric patients with hemophilia B and inhibitors due to disease rarity. We describe three patients diagnosed in childhood and followed up to 9 years. All three had allergic reactions to Factor IX, but two were later safely treated for bleeding episodes with activated prothrombin complex concentrates (APCC = FEIBA). The third was given only recombinant activated Factor VIIa. Based on ex vivo thrombin generation analysis, a new alternative treatment of combined bypassing agents was administered for bleeding episodes and several minor surgical procedures with no treatment-associated adverse events or thrombosis.<br /> (© 2018 Wiley Periodicals, Inc.)
Details
- Language :
- English
- ISSN :
- 1545-5017
- Volume :
- 65
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Pediatric blood & cancer
- Publication Type :
- Academic Journal
- Accession number :
- 30230231
- Full Text :
- https://doi.org/10.1002/pbc.27381